despit
avail
inactiv
vaccin
licens
year
influenza
viru
continu
caus
morbid
mortal
worldwid
constant
evolut
circul
influenza
viru
strain
emerg
new
strain
diminish
effect
annual
vaccin
reli
match
circul
influenza
strain
thu
continu
need
new
efficaci
vaccin
confer
crossclad
protect
avoid
need
biannual
reformul
season
influenza
vaccin
recombin
virusvector
vaccin
appeal
altern
classic
inactiv
vaccin
viru
vector
enabl
nativ
express
influenza
antigen
even
virul
influenza
virus
express
context
vector
improv
immunogen
addit
vector
vaccin
often
enabl
deliveri
vaccin
site
induct
immun
respiratori
tract
enabl
protect
influenza
viru
infect
moreov
abil
readili
manipul
viru
vector
produc
novel
influenza
vaccin
may
provid
quickest
path
toward
univers
vaccin
protect
influenza
virus
review
discuss
experiment
virusvector
vaccin
use
human
compar
licens
vaccin
hurdl
face
licensur
nextgener
influenza
viru
vaccin
season
influenza
worldwid
health
problem
caus
high
mobil
substanti
mortal
moreov
influenza
infect
often
worsen
preexist
medic
condit
vaccin
circul
influenza
strain
avail
updat
annual
mani
issu
still
present
includ
low
efficaci
popul
greatest
risk
complic
influenza
viru
infect
ie
young
elderli
despit
increas
vaccin
rate
influenzarel
hospit
increas
substanti
drug
resist
develop
two
four
current
approv
antivir
drug
adjuv
potenti
improv
efficaci
avail
current
inactiv
vaccin
liveattenu
virusvector
vaccin
still
consid
one
best
option
induct
broad
efficaci
immun
influenza
viru
gener
type
influenza
vaccin
avail
unit
state
trival
inactiv
influenza
vaccin
tiv
quadrival
influenza
vaccin
qiv
live
attenu
influenza
vaccin
laiv
trival
quadrival
form
three
type
inactiv
vaccin
includ
whole
viru
inactiv
split
viru
inactiv
subunit
vaccin
split
viru
vaccin
viru
disrupt
deterg
subunit
vaccin
ha
na
purifi
remov
viral
compon
tiv
administ
intramuscularli
contain
three
four
inactiv
virus
ie
two
type
strain
one
two
type
b
strain
tiv
efficaci
measur
induct
humor
respons
hemagglutinin
ha
protein
major
surfac
attach
glycoprotein
influenza
serum
antibodi
respons
ha
measur
hemagglutinationinhibit
hi
assay
strainspecif
hi
titer
consid
goldstandard
correl
immun
influenza
fourfold
increas
titer
postvaccin
hi
titer
consid
protect
protect
clinic
diseas
mainli
confer
serum
antibodi
howev
mucos
iga
antibodi
also
may
contribut
resist
infect
split
viru
inactiv
vaccin
induc
neuraminidas
na
specif
antibodi
respons
antina
antibodi
associ
protect
infect
human
current
naspecif
antibodi
respons
consid
correl
protect
laiv
administ
nasal
spray
contain
three
four
influenza
viru
strain
inactiv
vaccin
attenu
vaccin
backbon
laiv
temperaturesensit
coldadapt
replic
effect
core
bodi
temperatur
replic
mucosa
nasopharynx
laiv
immun
induc
serum
antibodi
respons
mucos
antibodi
respons
iga
cell
respons
robust
serum
antibodi
nasal
wash
mucos
antibodi
respons
associ
protect
infect
immun
respons
cytotox
lymphocyt
ctl
respons
may
contribut
protect
clear
correl
immun
laiv
current
licens
influenza
viru
vaccin
suffer
number
issu
inactiv
vaccin
reli
specif
antibodi
respons
ha
lesser
extent
na
protein
protect
immunodomin
portion
ha
na
molecul
undergo
constant
process
antigen
drift
natur
accumul
mutat
enabl
viru
evas
immun
thu
circul
influenza
b
strain
review
annual
antigen
match
current
vaccin
replac
vaccin
strain
may
occur
regularli
annual
vaccin
recommend
assur
protect
northern
hemispher
vaccin
strain
select
occur
februari
manufactur
begin
product
take
least
six
month
produc
million
vaccin
dose
requir
fall
predict
imperfect
manufactur
issu
vaccin
product
vaccin
efficaci
avail
compromis
laiv
recommend
popul
howev
gener
consid
effect
inactiv
vaccin
may
efficaci
children
laiv
reli
antigen
match
ha
na
antigen
replac
schedul
tiv
suggest
laiv
may
induc
broader
protect
tiv
due
divers
immun
respons
consist
induc
virusneutr
serum
mucos
antibodi
well
broadli
reactiv
cell
respons
overal
tiv
laiv
consid
safe
effect
recogn
need
improv
season
influenza
vaccin
moreov
improv
understand
immun
conserv
influenza
viru
antigen
rais
possibl
univers
vaccin
univers
antigen
like
requir
novel
vaccin
effect
deliveri
virusvector
vaccin
share
mani
advantag
laiv
well
uniqu
vector
recombin
dna
system
exist
allow
readi
manipul
modif
vector
genom
turn
enabl
modif
vector
attenu
viru
enhanc
immunogen
addit
ad
manipul
influenza
viru
antigen
mani
vector
extens
studi
use
vaccin
wild
type
form
viru
final
vaccin
vector
either
replicationdefect
caus
selflimit
infect
although
like
laiv
safeti
immunocompromis
individu
still
remain
concern
tabl
summar
benefit
concern
virusvector
vaccin
discuss
serotyp
adenoviru
mani
explor
vaccin
vector
live
adenoviru
vaccin
contain
serotyp
use
militari
decad
suggest
adenovirus
may
safe
widespread
vaccin
use
howev
safeti
concern
led
major
adenovirusbas
vaccin
develop
focu
replicationdefect
vector
adenoviru
moststudi
serotyp
test
gene
deliveri
anticanc
agent
well
infecti
diseas
vaccin
adenoviru
vector
attract
vaccin
vector
genom
stabl
varieti
recombin
system
avail
accommod
kb
recombin
genet
materi
adenoviru
nonenvelop
viru
rel
stabl
formul
longterm
storag
even
storag
six
month
room
temperatur
adenoviru
vaccin
grown
high
titer
exceed
plaqu
form
unit
pfu
per
ml
cultur
cell
viru
purifi
simpl
method
adenoviru
vaccin
also
deliv
via
multipl
rout
includ
intramuscular
inject
subcutan
inject
intraderm
inject
oral
deliveri
use
protect
capsul
intranas
deliveri
importantli
latter
two
deliveri
method
induc
robust
mucos
immun
respons
may
bypass
preexist
vector
immun
even
replicationdefect
adenoviru
vector
natur
immunostimulatori
effect
adjuv
recombin
antigen
deliv
adenoviru
extens
studi
vaccin
vector
human
diseas
first
report
use
adenoviru
vaccin
vector
influenza
demonstr
immunogen
recombin
adenoviru
express
ha
swine
influenza
viru
intramuscular
immun
mice
construct
induc
robust
neutral
antibodi
respons
protect
mice
challeng
heterolog
viru
ahong
replic
defect
vaccin
express
influenza
ha
also
test
human
express
ha
apuerto
deliv
human
epicutan
intranas
assay
safeti
immunogen
vaccin
well
toler
induc
seroconvers
intranas
administr
higher
convers
rate
higher
geometr
meant
hi
titer
clinic
trial
rad
vector
overal
success
demonstr
safeti
level
efficaci
vector
neg
overshadow
two
clinic
trial
failur
first
trial
gene
therapi
examin
highdos
intraven
deliveri
ad
vector
result
death
male
second
clinic
failur
use
hiv
vaccin
test
part
step
studi
phase
clinic
trial
studi
individu
vaccin
vaccin
vector
express
gag
pol
nef
gene
vaccin
induc
hivspecif
cell
respons
howev
studi
stop
interim
analysi
suggest
vaccin
achiev
efficaci
individu
high
preexist
antibodi
titer
might
increas
risk
acquir
subsequ
vaccineassoci
risk
confirm
two
instanc
suggest
advector
vaccin
unsaf
inefficaci
umbra
cast
clinic
trial
note
affect
interest
adenoviru
vaccin
interest
still
remain
immun
adenoviru
vector
induc
potent
cellular
humor
immun
respons
initi
tolllik
receptordepend
independ
pathway
induc
robust
proinflammatori
cytokin
respons
recombin
ad
vaccin
express
ha
antigen
pandem
highli
pathogen
avian
influenza
hpai
viru
hpaiv
avian
influenza
virus
test
efficaci
number
anim
model
includ
chicken
mice
ferret
shown
efficaci
provid
protect
challeng
sever
vector
explor
deliveri
nonha
antigen
influenza
nucleoprotein
np
matrix
protein
efficaci
nonha
antigen
led
inclus
habas
vaccin
improv
immunogen
broaden
breadth
humor
cellular
immun
howev
cell
neutral
antibodi
respons
gener
vector
vaccin
antigen
immunolog
memori
compon
reduc
efficaci
limit
repeat
use
one
drawback
vector
potenti
preexist
immun
altern
adenoviru
serotyp
explor
vector
particularli
nonhuman
uncommon
human
serotyp
nonhuman
adenoviru
vector
includ
nonhuman
primat
nhp
dog
sheep
pig
cow
bird
other
vector
infect
varieti
cell
type
gener
attenu
human
avoid
concern
preexist
immun
swine
nhp
bovin
adenovirus
express
ha
antigen
shown
induc
immun
compar
human
vaccin
recombin
replicationdefect
adenovirus
lowpreval
serotyp
also
shown
efficaci
low
preval
serotyp
adenoviru
type
evad
immun
respons
maintain
effect
antigen
deliveri
immunogen
primeboost
strategi
use
dna
protein
immun
conjunct
adenoviru
vaccin
booster
immun
also
explor
mean
avoid
preexist
immun
adenoassoci
virus
aav
first
explor
gene
therapi
vector
like
rad
vector
raav
broad
tropism
infect
varieti
host
tissu
prolifer
nonprolifer
cell
type
aav
gener
consid
vaccin
vector
wide
consid
poorli
immunogen
semin
studi
use
express
glycoprotein
show
viru
vaccin
vector
effect
induc
potent
cell
serum
antibodi
respons
therebi
open
door
raav
vaccineassoci
studi
aav
vector
system
number
engag
properti
wild
type
virus
nonpathogen
replic
incompet
human
recombin
aav
vector
system
even
attenu
member
parvoviru
famili
aav
small
nonenvelop
virus
stabl
amen
longterm
storag
without
cold
chain
limit
preexist
immun
avail
nonhuman
strain
vaccin
candid
elimin
concern
modif
vector
increas
immunogen
well
limit
studi
use
aav
vaccin
vector
influenza
aav
express
ha
antigen
first
shown
induc
protect
later
hybrid
aav
deriv
two
nonhuman
primat
isol
use
express
influenza
np
protect
challeng
mice
recent
follow
influenza
viru
pandem
raav
vector
gener
express
ha
np
matrix
protein
murin
immun
challeng
studi
raavha
raavnp
shown
protect
howev
mice
vaccin
raavha
np
robust
protect
also
mice
vaccin
raavha
raavnp
also
partial
protect
heterolog
challeng
recent
aav
vector
use
deliv
passiv
immun
influenza
studi
aav
use
deliv
antibodi
transgen
encod
broadli
crossprotect
antiinfluenza
monoclon
antibodi
vivo
express
intramuscular
intranas
deliveri
aav
shown
protect
number
influenza
viru
challeng
mice
ferret
includ
virus
studi
suggest
raav
vector
promis
vaccin
immunoprophylaxi
vector
point
approxim
phase
iii
ii
iii
raav
clinic
trial
open
complet
review
focus
upon
gene
transfer
studi
yet
limit
safeti
data
use
raav
vaccin
alphavirus
positivesens
singlestrand
rna
virus
togavirida
famili
varieti
alphavirus
develop
vaccin
vector
includ
semliki
forest
viru
sfv
sindbi
sin
viru
venezuelan
equin
enceph
vee
viru
well
chimer
virus
incorpor
portion
sin
vee
virus
replic
defect
vaccin
replicon
encod
viral
structur
protein
portion
genom
replac
transgen
materi
structur
protein
provid
cell
cultur
product
system
one
import
featur
replicon
system
selfrepl
natur
rna
despit
partial
viral
genom
rna
selfrepl
express
transgen
high
level
sin
sfv
vee
test
efficaci
vaccin
vector
influenza
viru
veebas
replicon
system
encod
ha
demonstr
induc
potent
haspecif
immun
respons
protect
challeng
murin
model
despit
repeat
immun
vector
express
control
antigen
suggest
preexist
immun
may
issu
replicon
vaccin
separ
studi
develop
vee
replicon
system
express
ha
ahong
demonstr
vari
efficaci
ovo
vaccin
vaccin
chick
recombin
sin
viru
use
vaccin
vector
deliv
cell
epitop
wellcharacter
np
epitop
transgen
express
sin
system
shown
immunogen
mice
prime
robust
cell
respons
reduc
influenza
viru
titer
challeng
recent
vee
replicon
system
express
ha
protein
shown
protect
young
adult
age
mice
lethal
homolog
challeng
vee
replicon
system
particularli
appeal
vee
target
antigenpres
cell
lymphat
tissu
prime
rapid
robust
immun
respons
vee
replicon
system
induc
robust
mucos
immun
respons
intranas
subcutan
immun
subcutan
immun
viruslik
replicon
particl
vrp
express
hainduc
antigenspecif
system
igg
fecal
iga
antibodi
vrp
deriv
vee
viru
develop
candid
vaccin
cytomegaloviru
cmv
phase
clinic
trial
cmv
vrp
show
vaccin
immunogen
induc
cmvneutral
antibodi
respons
potent
cell
respons
moreov
vaccin
well
toler
consid
safe
separ
clinic
trial
assess
efficaci
repeat
immun
vrp
express
tumor
antigen
vaccin
safe
despit
high
vectorspecif
immun
initi
immun
continu
boost
transgenespecif
immun
respons
upon
boost
addit
clinic
data
need
report
suggest
alphaviru
replicon
system
vrp
may
safe
efficaci
even
face
preexist
immun
baculoviru
extens
use
produc
recombin
protein
recent
baculovirusderiv
recombin
ha
vaccin
approv
human
use
first
avail
use
unit
state
influenza
season
baculovirus
also
explor
vaccin
vector
baculovirus
number
advantag
vaccin
vector
virus
extens
studi
protein
express
pesticid
use
readili
manipul
vector
accommod
larg
gene
insert
show
limit
cytopath
effect
mammalian
cell
shown
infect
express
gene
interest
spectrum
mammalian
cell
insect
promot
effect
mammalian
gene
express
appropri
promot
clone
baculoviru
vaccin
vector
baculoviru
vector
test
influenza
vaccin
first
report
vaccin
use
autographa
californica
nuclear
polyhedrosi
viru
acnpv
express
ha
control
cag
promot
accagha
intramuscular
intranas
intraderm
intraperiton
immun
mice
accagha
elicit
haspecif
antibodi
respons
howev
intranas
immun
provid
protect
lethal
challeng
interestingli
intranas
immun
wild
type
acnpv
also
result
protect
challeng
robust
innat
immun
respons
baculoviru
provid
nonspecif
protect
subsequ
influenza
viru
infect
studi
demonstr
specif
protect
antigenspecif
immun
respons
potenti
adjuv
effect
innat
respons
baculoviru
pseudotyp
virus
also
explor
g
protein
vesicular
stomat
viru
control
insect
polyhedron
promot
ha
hpaiv
control
cmv
promot
use
gener
bvgha
intramuscular
immun
mice
chicken
bvgha
elicit
strong
hi
vn
serum
antibodi
respons
respons
protect
challeng
separ
studi
demonstr
efficaci
use
bival
pseudotyp
baculoviru
vector
baculoviru
also
use
gener
inactiv
particl
vaccin
ha
incorpor
commerci
baculoviru
vector
control
promot
white
spot
syndrom
viru
result
recombin
viru
propag
insect
cell
inactiv
particl
vaccin
intranas
deliveri
cholera
toxin
b
adjuv
elicit
robust
hi
titer
protect
lethal
challeng
oral
deliveri
encapsul
vaccin
induc
robust
serum
hi
titer
mucos
iga
titer
mice
protect
hpaiv
challeng
recent
coformul
inactiv
baculoviru
vector
also
shown
effect
mice
grow
data
potenti
use
baculoviru
pseudotyp
baculoviru
vaccin
vector
efficaci
data
mammalian
anim
model
mice
lack
also
data
safeti
human
reduc
enthusiasm
baculoviru
vaccin
vector
influenza
time
newcastl
diseas
viru
ndv
singlestrand
negativesens
rna
viru
caus
diseas
poultri
ndv
number
appeal
qualiti
vaccin
vector
avian
viru
littl
preexist
immun
ndv
human
ndv
propag
high
titer
chicken
egg
cell
cultur
paramyxoviru
dna
phase
viru
lifecycl
reduc
concern
integr
event
level
gene
express
driven
proxim
leader
sequenc
end
viral
genom
gradient
gene
express
enabl
attenu
rearrang
genom
insert
transgen
within
genom
final
pathogen
ndv
larg
determin
featur
fusion
protein
enabl
readi
attenu
vaccin
vector
revers
genet
method
allow
ndv
rescu
plasmid
express
viral
rna
polymeras
nucleocapsid
protein
first
report
process
enabl
manipul
ndv
genom
well
incorpor
transgen
develop
ndv
vector
influenza
first
infecti
diseas
target
recombin
ndv
rndv
vector
ha
protein
insert
hitchner
vaccin
strain
ha
protein
express
infect
cell
incorpor
infecti
virion
viru
attenu
compar
parent
vaccin
strain
induc
robust
serum
antibodi
respons
protect
homolog
influenza
viru
challeng
murin
model
infect
subsequ
rndv
test
vaccin
vector
hpaiv
vari
efficaci
influenza
viru
infect
poultri
vaccin
ad
benefit
potenti
provid
protect
influenza
viru
ndv
infect
ndv
also
explor
vaccin
vector
human
two
nhp
studi
assess
immunogen
efficaci
rndv
express
ha
na
intranas
intratrach
deliveri
rndvha
rndvna
vaccin
induc
serum
mucos
antibodi
respons
protect
hpaiv
challeng
ndv
limit
clinic
data
howev
phase
phase
iii
clinic
trial
shown
ndv
vector
welltoler
even
high
dose
deliv
intraven
result
promis
addit
studi
need
advanc
ndv
human
vaccin
vector
influenza
parainfluenza
viru
type
paramyxoviru
vaccin
vector
explor
deliveri
influenza
infecti
diseas
vaccin
antigen
recent
describ
vaccin
vector
similar
rna
virus
number
featur
make
attract
vaccin
vector
exampl
stabl
rna
genom
dna
phase
viru
replic
cycl
reduc
concern
host
genom
integr
modif
grown
high
titer
mammalian
vaccin
cell
cultur
substrat
cytopath
allow
extend
cultur
harvest
vaccin
viru
like
ndv
gradient
gene
express
insert
transgen
differ
locat
genom
variabl
attenu
viru
alter
transgen
express
broad
tropism
infect
mani
cell
type
tissu
speci
without
caus
clinic
diseas
although
associ
kennel
dog
revers
genet
system
first
use
insert
ha
gene
genom
hemagglutininneuraminidas
hn
gene
larg
l
polymeras
gene
similar
ndv
ha
express
high
level
infect
cell
replic
similarli
wild
type
viru
importantli
pathogen
immunodefici
mice
addit
singl
intranas
immun
murin
model
influenza
infect
shown
induc
neutral
antibodi
respons
protect
viru
express
homolog
ha
protein
also
explor
vaccin
hpaiv
recombin
vaccin
express
ha
np
test
efficaci
murin
challeng
model
mice
intranas
vaccin
singl
dose
vaccin
robust
serum
mucos
antibodi
respons
protect
lethal
challeng
notabl
although
cellular
immun
respons
appear
contribut
protect
serum
antibodi
suffici
protect
challeng
intramuscular
immun
also
shown
effect
induc
neutral
antibodi
respons
protect
lethal
influenza
viru
challeng
express
np
protein
hpaiv
also
efficaci
murin
immun
challeng
model
singl
intranas
immun
induc
robust
cell
respons
protect
homolog
heterosubtyp
viru
challeng
current
clinic
safeti
data
use
human
howev
live
compon
veterinari
vaccin
kennel
year
veterinarian
dog
owner
expos
live
without
report
diseas
combin
preclin
data
varieti
anim
model
suggest
vector
like
safe
human
preexist
immun
concern
virusvector
vaccin
note
data
level
preexist
immun
human
howev
studi
evalu
efficaci
vaccin
canin
previous
vaccin
kennel
cough
show
induct
robust
serum
antibodi
respons
well
high
serum
antibodi
level
vaccin
suggest
preexist
immun
vector
may
affect
immunogen
vaccin
even
repeat
use
poxviru
vaccin
long
histori
notabl
hallmark
respons
erad
smallpox
termin
smallpox
viru
vaccin
program
result
larg
popul
individu
provid
opportun
use
poxvirus
vector
without
preexist
immun
concern
poxvirusvector
vaccin
first
propos
use
two
report
recombin
vaccinia
virus
encod
express
function
thymidin
kinas
gene
herp
viru
within
year
vaccinia
viru
encod
ha
viru
shown
express
function
ha
protein
cleav
subunit
immunogen
rabbit
hamster
subsequ
ten
primari
influenza
protein
express
vaccin
viru
earli
work
intact
vaccinia
viru
vector
rais
safeti
concern
substanti
reactogen
hinder
recombin
vaccin
develop
two
vaccinia
vector
develop
address
safeti
concern
modifi
vaccinia
viru
ankara
mva
strain
attenu
passag
time
chick
embryo
fibroblast
cultur
second
new
york
vaccinia
viru
nyvac
plaquepurifi
clone
copenhagen
vaccin
strain
ration
attenu
delet
open
read
frame
modifi
vaccinia
viru
ankara
mva
develop
prior
smallpox
erad
reduc
prevent
advers
effect
smallpox
vaccin
serial
tissu
cultur
passag
mva
result
loss
genom
establish
growth
restrict
avian
cell
defect
affect
late
stage
viru
assembl
nonavian
cell
featur
enabl
use
vector
singleround
express
vector
nonpermiss
host
interestingli
two
decad
ago
recombin
mva
express
ha
np
influenza
viru
shown
effect
lethal
influenza
viru
challeng
murin
model
subsequ
mva
express
variou
antigen
season
pandem
equin
hpai
virus
shown
efficaci
murin
ferret
nhp
equin
challeng
model
mva
vaccin
effect
stimul
cellular
humor
immun
exampl
abort
infect
provid
nativ
express
influenza
antigen
enabl
robust
antibodi
respons
nativ
surfac
viral
antigen
concurr
intracellular
influenza
peptid
express
pox
vector
enter
class
mhc
antigen
process
present
pathway
enabl
induct
cell
antivir
respons
mva
also
induc
cell
respons
contribut
magnitud
antigenspecif
effector
function
mva
also
potent
activ
earli
innat
immun
respons
enhanc
adapt
immun
respons
earli
smallpox
vaccin
develop
recent
vaccin
vector
develop
mva
undergon
extens
safeti
test
shown
attenu
sever
immunocompromis
anim
safe
use
children
adult
elderli
immunocompromis
person
extens
preclin
data
recombin
mva
vaccin
express
influenza
antigen
test
clinic
trial
shown
safe
immunogen
human
result
combin
data
noninfluenza
clinic
preclin
studi
support
mva
lead
viralvector
candid
vaccin
nyvac
vector
highli
attenu
vaccinia
viru
strain
nyvac
replicationrestrict
howev
grow
chick
embryo
fibroblast
vero
cell
enabl
vaccinescal
product
nonpermiss
cell
critic
late
structur
protein
produc
stop
replic
immatur
virion
stage
nyvac
attenu
consid
safe
use
human
age
howev
predominantli
induc
cell
respons
differ
compar
mva
mva
nyvac
provok
robust
humor
respons
deliv
mucos
induc
mucos
antibodi
respons
limit
explor
nyvac
vaccin
vector
influenza
viru
howev
vaccin
express
ha
shown
induc
potent
neutral
antibodi
respons
protect
challeng
swine
strong
safeti
efficaci
data
use
nyvac
mvavector
influenza
vaccin
preexist
immun
remain
concern
although
smallpox
vaccin
campaign
result
popul
peopl
initi
mva
nyvac
vaccin
program
hiv
influenza
pathogen
rapidli
reduc
suscept
popul
signific
interest
develop
poxvector
influenza
viru
vaccin
current
influenza
vaccin
strategi
reli
upon
regular
immun
vaccin
match
circul
strain
would
like
limit
use
andor
efficaci
poxvirusvector
influenza
viru
vaccin
regular
season
use
intriguingli
nyvac
may
advantag
use
influenza
vaccin
vector
immun
vector
induc
weaker
vaccinespecif
immun
respons
compar
poxviru
vaccin
featur
may
address
concern
surround
preexist
immun
poxvirusvector
vaccin
yet
approv
use
human
grow
list
licens
poxviru
veterinari
use
includ
fowlpoxand
canarypoxvector
vaccin
avian
equin
influenza
virus
respect
fowlpoxvector
vaccin
express
avian
influenza
viru
ha
antigen
ad
benefit
provid
protect
fowlpox
infect
current
least
ten
poxvirusvector
vaccin
licens
veterinari
use
poxviru
vector
potenti
use
vaccin
vector
human
similar
first
use
cowpox
vaccin
smallpox
avail
nonhuman
poxviru
vector
extens
anim
safeti
efficaci
data
may
address
issu
preexist
immun
human
vaccin
strain
although
crossreact
origin
describ
cowpox
could
also
limit
use
influenza
vaccin
util
vesicular
stomat
viru
vsv
rhabdoviru
vaccin
vector
number
advantag
share
rna
viru
vaccin
vector
live
replicationdefect
vsv
vaccin
vector
shown
immunogen
like
paramyxovirida
rhabdovirida
genom
gradient
gene
express
enabl
attent
select
vaccin
gene
insert
genom
rearrang
vsv
number
advantag
includ
broad
tissu
tropism
potenti
intramuscular
intranas
immun
latter
deliveri
method
enabl
induct
mucos
immun
elimin
needl
requir
vaccin
also
littl
evid
vsv
seroposit
human
elimin
concern
preexist
immun
although
repeat
use
may
concern
also
vsv
vaccin
produc
use
exist
mammalian
vaccin
manufactur
cell
line
influenza
antigen
first
express
vsv
vector
ha
na
shown
express
function
protein
incorpor
recombin
vsv
particl
subsequ
vsvha
express
ha
protein
shown
immunogen
protect
mice
lethal
influenza
viru
challeng
reduc
safeti
concern
attenu
vsv
vector
develop
one
candid
vaccin
truncat
vsv
g
protein
second
candid
defici
g
protein
express
reli
g
protein
express
helper
vaccin
cell
line
provid
viru
receptor
vector
found
attenu
mice
maintain
immunogen
recent
singlecycl
replic
vsv
vaccin
test
efficaci
hpaiv
vsv
vector
express
ha
ahong
shown
immunogen
induc
crossreact
antibodi
respons
protect
challeng
heterolog
challeng
murin
nhp
model
vsv
vector
without
potenti
concern
vsv
caus
diseas
number
speci
includ
human
viru
also
potenti
neuroinvas
speci
although
nhp
studi
suggest
concern
human
also
incorpor
influenza
antigen
virion
may
provid
benefit
immunogen
chang
tropism
attenu
could
aris
incorpor
differ
influenza
glycoprotein
evid
howev
current
human
safeti
data
vsvvector
vaccin
experiment
data
promis
addit
work
need
consider
human
influenza
vaccin
current
influenza
vaccin
reli
match
ha
antigen
vaccin
circul
strain
provid
strainspecif
neutral
antibodi
respons
signific
interest
develop
univers
influenza
vaccin
would
requir
annual
reformul
provid
protect
robust
durabl
immun
vaccin
reli
gener
focus
immun
respons
highli
conserv
portion
viru
refractori
mutat
tradit
vaccin
may
suitabl
vaccin
strategi
howev
vector
vaccin
abil
readili
modifi
express
transgen
compat
applic
np
protein
explor
univers
vaccin
antigen
decad
earli
work
recombin
viral
vector
demonstr
immun
vaccin
express
influenza
antigen
induc
potent
cell
respons
respons
even
ha
antigen
could
crossprotect
number
studi
shown
immun
np
express
aav
alphaviru
vector
mva
vector
system
induc
potent
cell
respons
protect
influenza
viru
challeng
np
protein
highli
conserv
across
influenza
virus
npspecif
cell
protect
heterolog
even
heterosubtyp
viru
challeng
protein
also
highli
conserv
express
surfac
infect
cell
although
lesser
extent
surfac
viru
particl
much
vaccin
work
area
focus
viruslik
subunit
particl
express
ectodomain
howev
studi
util
dnaprim
radboost
strategi
vaccin
entir
protein
shown
antigen
immunogen
protect
studi
antibodi
protein
protect
homolog
heterosubtyp
challeng
includ
hpaiv
challeng
recent
np
combin
induc
broadli
crossreact
cell
antibodi
respons
vaccin
express
antigen
shown
protect
challeng
histor
ha
wide
consid
univers
vaccin
antigen
howev
recent
identif
viru
neutral
monoclon
antibodi
crossreact
mani
subtyp
influenza
viru
present
opportun
design
vaccin
antigen
prime
focus
antibodi
respons
highli
conserv
region
recogn
monoclon
antibodi
major
broadli
crossreact
antibodi
recogn
region
stalk
ha
protein
ha
stalk
gener
less
immunogen
compar
globular
head
ha
protein
approach
util
ha
protein
immunogen
ha
stalk
vaccin
design
use
dna
viruslik
particl
mva
howev
approach
amen
express
virus
vector
describ
goal
vaccin
protect
infect
diseas
induc
populationbas
immun
reduc
elimin
viru
transmiss
within
popul
clear
current
licens
influenza
vaccin
fulli
met
goal
specif
induc
longterm
robust
immun
number
vaccinerel
issu
must
address
populationbas
influenza
vaccin
strategi
optim
concept
one
size
fit
vaccin
need
updat
given
recent
abil
probe
virushost
interfac
rna
interfer
approach
facilit
identif
host
gene
affect
viru
replic
immun
diseas
also
need
revis
current
influenza
viru
vaccin
strategi
atrisk
popul
particularli
either
end
age
spectrum
exampl
improv
vaccin
regim
might
includ
use
vector
influenza
viru
vaccin
express
ha
na
andor
np
protein
two
current
circul
influenza
subtyp
influenza
b
strain
vaccin
take
vaccin
antigen
level
issu
induc
protect
immun
recombin
liveattenu
replicationdefici
influenza
virus
may
offer
advantag
approach
vector
vaccin
construct
express
fulllength
influenza
viru
protein
well
gener
conform
restrict
epitop
featur
critic
gener
appropri
humor
protect
inclus
intern
influenza
antigen
vector
vaccin
also
induc
high
level
protect
cellular
immun
gener
sustain
immun
advantag
induc
immun
site
induct
immun
natur
infect
case
respiratori
tract
sever
vector
vaccin
target
respiratori
tract
typic
vector
vaccin
gener
antigen
week
immun
contrast
subunit
vaccin
increas
presenc
level
vaccin
antigen
contribut
help
sustain
durabl
memori
immun
respons
even
augment
select
higher
affin
antibodi
secret
cell
enhanc
memori
respons
part
link
intrins
augment
immun
induc
vector
thu
weaker
antigen
typic
ha
vector
vaccin
capac
overcom
real
limit
achiev
robust
durabl
protect
meet
mandat
season
influenza
vaccin
develop
difficult
respond
pandem
strain
even
challeng
issu
influenza
vaccin
strain
select
base
recent
circul
virus
often
reflect
recommend
world
health
organ
process
cumbersom
strain
influenza
virus
use
vaccin
manufactur
wildtyp
virus
rather
reassort
hybrid
virus
contain
least
ha
na
gene
segment
target
strain
gene
segment
master
strain
properti
high
growth
fertil
hen
egg
addit
process
requir
time
qualiti
control
specif
hpai
virus
process
may
fail
natur
virus
contrast
viralvector
vaccin
rel
easi
manipul
produc
wellestablish
safeti
profil
sever
viralbas
vector
current
employ
antigen
deliveri
system
includ
poxvirus
adenovirus
baculoviru
paramyxoviru
rhabdoviru
other
howev
major
human
clinic
trial
assess
viralvector
influenza
vaccin
use
poxviru
adenoviru
vector
vector
approach
uniqu
featur
differ
stage
develop
combin
success
approach
support
virusvector
vaccin
approach
whole
issu
preexist
immun
cold
chain
requir
linger
safeti
concern
overcom
howev
approach
make
progress
address
issu
approach
still
viabl
virusvector
vaccin
hold
particular
promis
vaccin
univers
focus
antigen
tradit
vaccin
method
suit
efficaci
deliveri
antigen
promis
approach
current
develop
arguabl
target
conserv
ha
stalk
region
epitop
given
find
date
virusvector
vaccin
hold
great
promis
may
overcom
current
limit
influenza
vaccin
